Document is current
Any future updates will be listed below
-
Authors
Wang, Bo
Iriguchi, Shoichi
Waseda, Masazumi
Ueda, Norihiro
Ueda, Tatsuki
Xu, Huaigeng https://orcid.org/0000-0002-4415-1287
Minagawa, Atsutaka
Ishikawa, Akihiro
Yano, Hisashi
Ishi, Tomoko
Ito, Ryoji https://orcid.org/0000-0003-2903-2332
Goto, Motohito https://orcid.org/0000-0001-6288-4583
Takahashi, Riichi
Uemura, Yasushi
Hotta, Akitsu
Kaneko, Shin https://orcid.org/0000-0003-2291-4586
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science
Japan Agency for Medical Research and Development
- License Information
-
More Information
Article History
Received: 5 December 2019
Accepted: 13 April 2021
First Online: 17 May 2021
Competing interests
: S.K. is a founder, shareholder and chief scientific officer at Thyas Co. Ltd and received research funding from Takeda Pharmaceutical Co. Ltd, Kirin Co. Ltd, Terumo Co. Ltd, Tosoh Co. Ltd and Thyas Co. Ltd.
